Liposomal delivery of hydrophobic RAMBAs provides good bioavailability and significant enhancement of retinoic acid signalling in neuroblastoma tumour cells by Bilip, Maja et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=idrt20
Journal of Drug Targeting
ISSN: 1061-186X (Print) 1029-2330 (Online) Journal homepage: https://www.tandfonline.com/loi/idrt20
Liposomal delivery of hydrophobic RAMBAs
provides good bioavailability and significant
enhancement of retinoic acid signalling in
neuroblastoma tumour cells
Maja Bilip, Shreya Shah, Mayuran Mathiyalakan, Aristides D. Tagalakis,
Stephen L. Hart, Ruhina Maeshima, Simon Eaton, Michael Orford, Elsa Irving,
Alessia Di Florio, Claire Simons & Andrew W. Stoker
To cite this article: Maja Bilip, Shreya Shah, Mayuran Mathiyalakan, Aristides D. Tagalakis,
Stephen L. Hart, Ruhina Maeshima, Simon Eaton, Michael Orford, Elsa Irving, Alessia Di Florio,
Claire Simons & Andrew W. Stoker (2020): Liposomal delivery of hydrophobic RAMBAs provides
good bioavailability and significant enhancement of retinoic acid signalling in neuroblastoma tumour
cells, Journal of Drug Targeting, DOI: 10.1080/1061186X.2019.1710157
To link to this article:  https://doi.org/10.1080/1061186X.2019.1710157
© 2020 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group
View supplementary material 
Accepted author version posted online: 04
Jan 2020.
Published online: 14 Jan 2020.
Submit your article to this journal 
Article views: 126 View related articles 
View Crossmark data
ORIGINAL ARTICLE
Liposomal delivery of hydrophobic RAMBAs provides good bioavailability and
significant enhancement of retinoic acid signalling in neuroblastoma tumour cells
Maja Bilipa, Shreya Shaha, Mayuran Mathiyalakana, Aristides D. Tagalakisa†, Stephen L. Harta, Ruhina Maeshimaa,
Simon Eatona, Michael Orforda, Elsa Irvinga, Alessia Di Florioa, Claire Simonsa,b and Andrew W. Stokera
aGreat Ormond Street Institute of Child Health, UCL, London, UK; bSchool of Pharmacy and Pharmaceutical Sciences, College of Biomedical and
Life Sciences, Cardiff University, Cardiff, UK
ABSTRACT
Retinoid treatment is employed during residual disease treatment in neuroblastoma, where the aim is to
induce neural differentiation or death in tumour cells. However, although therapeutically effective, reti-
noids have only modest benefits and suffer from poor pharmacokinetic properties. In vivo, retinoids
induce CYP26 enzyme production in the liver, enhancing their own rapid metabolic clearance, while retin-
oid resistance in tumour cells themselves is considered to be due in part to increased CYP26 production.
Retinoic acid metabolism blocking agents (RAMBAs), which inhibit CYP26 enzymes, can improve retinoic
acid (RA) pharmacokinetics in pre-clinical neuroblastoma models. Here, we demonstrate that in cultured
neuroblastoma tumour cells, RAMBAs enhance RA action as seen by morphological differentiation, AKT
signalling and suppression of MYCN protein. Although active as retinoid enhancers, these RAMBAs are
highly hydrophobic and their effective delivery in humans will be very challenging. Here, we demonstrate
that such RAMBAs can be loaded efficiently into cationic liposomal particles, where the RAMBAs achieve
good bioavailability and activity in cultured tumour cells. This demonstrates the efficacy of RAMBAs in
enhancing retinoid signalling in neuroblastoma cells and shows for the first time that liposomal delivery
of hydrophobic RAMBAs is a viable approach, providing novel opportunities for their delivery and applica-
tion in humans.
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Introduction
Neuroblastoma is a paediatric, peripheral nervous system cancer,
accounting for 15% of childhood cancer deaths [1] and it presents
a stubborn clinical challenge. In aggressive disease, multimodal
treatments are followed by maintenance treatment for residual
disease, which includes the vitamin A derivative, retinoic acid (RA)
[2]. RA induces neuroblastoma tumour cell differentiation or death
in a range of neuroblastoma-derived cells in culture [3,4].
Although it is uncertain exactly how RA influences tumour cell
behaviour in patients, the treatment does provide modest
improvements in event-free survival [2,5]. Nevertheless, the
approach of dosing infants and young children with 13-cis retinoic
acid (13-cis-RA) is challenging, with sub-optimal exposure [2,6]
and dose-limiting toxicities [2,6]. RA action in vivo is further ham-
pered by its rapid metabolism by cytochrome P450 enzymes in
the liver and the tumour [7]. Chronic induction of P450 enzymes
may also underlie a proportion of RA resistance cases [8,9].
Further improvements in RA efficacy in vivo are therefore needed
and this could be relevant to a range of cancers where retinoids
are employed therapeutically [10,11].
In neuroblastoma treatment, 13-cis-RA is viewed as a pro-drug,
with its isomer, all-trans RA (ATRA), being the biological effector
inside cells [12–14]. ATRA transcriptionally auto-induces P450
enzymes of the CYP26 subclass, triggering its own destruction.
These enzymes have thus become druggable targets of interest,
since they are largely responsible for RA clearance during treat-
ment [12]. CYP26 inhibitors are known as RA metabolism blocking
agents (RAMBAs) and they hold the potential of improving the
clinical benefit of retinoid treatments. Numerous RAMBAs exist
[15–20] and these can raise the effective intracellular concentra-
tions or serum concentrations of RA [18,21]. One of these, liaro-
zole, decreases the induced loss of ATRA in serum in acute
promyelocytic leukaemia patients [22], suggesting a potential
approach for suppressing retinoid resistance. Another RAMBA,
R116010, is highly CYP26-specific with low IC50 and good anti-
tumour activity in RA-treated breast cancer models [13,23,24].
R116010 also blocks CYP26 action both in SH-SY5Y neuroblastoma
cells and in the liver, leading to increased serum levels of both
ATRA and 13-cis-RA in mice [18]. It is possible therefore that
RAMBAs could enhance retinoid action in neuroblastoma tumour
cells themselves, inducing differentiation, cell death and N-Myc
suppression, although this has not been demonstrated directly.
To further improve the pharmacokinetics of retinoids in vivo,
there is a need for more effective delivery systems for some of
the most potent RAMBAs. In this study, we have used RAMBAs
based on imidazole (RAMBA C2) and on triazole (RAMBA C17),
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these having similar, high specificities and in vitro EC50 values to
R116010 [19,20]. C2 and C17, however, are highly hydrophobic
compounds and impractical for use in standard oral or intraven-
ous delivery and are therefore not suitable as drugs in this form.
Improved delivery and targeting of drugs can nevertheless be
achieved using nanotechnology, as evidenced in pre- clinical data
using several drugs in neuroblastoma [25–27] and other solid
tumours [28]. Liposomes for example have successfully enhanced
drug actions by improving stability, serum longevity and thera-
peutic efficacy [29]. They are suitable for hydrophobic compounds
and may also override drug resistance mechanisms [30,31].
Nanoparticles are also known to take advantage of tumour vascu-
lar leakiness to more specifically access tumour cells in solid
tumours including neuroblastoma [25,28,32]. For RAMBAs, this
approach has not been documented to date and we hypothesised
that liposomal delivery would improve bioavailability and making
such compounds more accessible for use in humans. Our experi-
mental model in cultured tumour cells would thus provide a proof
of principle that could potentially augment future application of
RAMBA-based therapy in vivo.
The objectives in this study were, therefore, to first demon-
strate the effectiveness of RAMBAs in enhancing a range of RA
actions in neuroblastoma cells, and then to provide a proof of
principle that RAMBAs can be effectively delivered to tumour cells
using liposomal systems.
Materials and methods
Chemicals and antibodies
Chemicals were from Sigma-Aldrich (St. Louis, MO) unless other-
wise stated. ATRA and 13-cis-RA (Sigma-Aldrich, St. Louis, MO)
were dissolved in either ethanol or DMSO at 10mM or 50mM,
respectively, and protected from light at –20 C. RAMBAs methyl
2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]-3-(1H-1,2,4-triazol-
1-yl)propanoate (compound 17; C17; molecular weight 400.5) and
methyl 3-(1H-imidazol-1-yl)-2,2-dimethyl-3-(4-(naphthalen-2-ylami-
no)phenyl)propanoate (compound 2; C2; molecular weight 399.5)
were generated as described [19] and were dissolved in ethanol
at 50mM (C17) and 1mM (C2; maximal solubility in this solvent).
Antibodies were sourced as follows: anti-N-myc (B8.4.B; Insight
Biotechnology, Wembley, UK); anti-phospho-Ser472-AKT (ab4060;
Cell Signaling Technology, Danvers, MA); anti-AKT (ab9272; Cell
Signaling Technology, Danvers, MA); anti-actin (A5316; Sigma-
Aldrich, St. Louis, MO); anti-GAPDH (14C10; Cell Signaling
Technology, Danvers, MA). HRP-linked secondary antibodies were
purchased from DAKO Ltd. (Bucks, UK).
Cell culture
Human immortalised cell lines SK-N-SH and IMR32 were obtained
from ATCC, KELLY/N206 was a gift from Frank Speleman,
University of Ghent (STR genotyped), and LAN-5 was from the
Children’s Oncology Group Repository (Lubbock, TX). All cells have
been validated by short tandem repeat profiling (LGC Standards)
and are mycoplasma tested. Cells were maintained at 37 C, 5%
CO2. SK-N-SH were cultured in minimum essential medium Eagle,
1% penicillin/streptomycin, 10% foetal bovine serum and 2mM L-
glutamine. LAN-5 and N206 cells were cultured in RPMI
1640þGlutaMAXTM (Invitrogen, Carlsbad, CA), 10% foetal bovine
serum and 1% penicillin/streptomycin, with 25mM HEPES pH7
(Fisher Scientific, Waltham, MA).
Immunoblotting
Cells were lysed in 50mM Tris–Base pH 7.6, 150mM NaCl, 1%
Triton X-100, 1 protease inhibitors, 25mM sodium fluoride and
1mM sodium vanadate. Proteins were separated by polyacryl-
amide electrophoresis and transferred to PVDF (Immobilon-P).
Immunodetection was performed using HRP-linked secondary
antibodies, and Pierce ECL 2 Substrate (Thermo Scientific,
Waltham, MA) and chemiluminescence film (Amersham Hyperfilm
ECL, GE Healthcare, Chicago, IL).
Liposomes
The lipids 1,2-di-O-octadecenyl-3-trimethylammonium propane
(DOTMA), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and
cholesterol were purchased from Avanti Polar Lipids (Alabaster,
AL). For empty liposomes DOTMA, DOPC and cholesterol were dis-
solved in chloroform in a final volume of 500 ml at a molar ratio
of 37.5%:37.5%:25%. RAMBA C2 and C17 were dissolved in ethanol
and added at a 10% molar ratio to lipids DOTMA (35%), DOPC
(35%) and cholesterol (20%). Chloroform was rotary evaporated
(B€UCHI Labortechnik AG, Flawil, Switzerland) and lipids were rehy-
drated in nuclease-free water, rotating overnight, to form lipo-
somes at either 1mg/ml or 2mg/ml lipids. For the 2mg/ml
mixture, this equates to the equivalent of 1.1mM DOTMA,
0.11mM DOPC and 0.64mM cholesterol, and in these liposomes
the RAMBAs were packaged at a maximal potential concentration
of 95.7lg per ml (0.24mM) in the liposome solution. After synthe-
sis, liposomes were sonicated for 30–45min, with the aim of
achieving a mean size of between 80 and 160 nm. Size and charge
were assessed with a Zetasizer Nano ZS (Malvern Panalytical,
Worcestershire, UK). Liposomes were stored at 4 C. To dialyse lip-
osomes, slide-A-LyzerTM MINI devices (Thermo Fisher Scientific,
Waltham, MA; molecular weight 10 kDa; capacity 15ml) were used
with 500 ml liposomes and this was dialysed against 13.5ml dis-
tilled water for 24 h at 4 C, with one water change.
Cell viability assays
Cells were plated at 3000 cells per well in 96-well plates. After
24 h, triplicate wells of cells were treated with chemicals and incu-
bated for five or six days, then assayed for cell number using resa-
zurin (R&D Systems, Minneapolis, MN) as per the manufacturer’s
guidelines. Reaction product was measured using fluorescence at
540 nm excitation and 590 nm emission wavelengths, in a
FLUOstar Optima (BMG Labtech, Aylesbury, UK).
Neurite outgrowth assays
Cells were treated and either then photographed live or after 4%
paraformaldehyde fixation. Five to 10 fields of view were captured
under phase contrast per tissue culture well. Neurites greater than
one cell body length were measured using the NeuroJ plugin for
ImageJ and cell bodies were counted using the ‘point-count’ func-
tion. Light microscopy was performed at the Light Microscopy
Core Facility, UCL GOS Institute of Child Health. Where statistical
analysis was used, a univariate ANOVA analysis was performed
using SPSS with 95% confidence intervals. Post hoc tests included
a Bonferroni adjustment and a Dunnett test where stated.
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Real-time PCR
LAN5 and SK-N-SH cells were plated at 3 105 per well in six-well
plates. The next day, cells were treated with 0.1lM or 0.5lM
ATRA. After 72 h, RNA was extracted and DNAse treated using the
TURBO DNA-free kit (Ambion, Austin, TX) according to the manu-
facturer’s recommendations. cDNA was synthesised from 1 mg of
total RNA using Transcriptor First Strand cDNA synthesis (Roche,
Basel, Switzerland) according to the manufacturer’s recommenda-
tions. Real-time PCR was performed using iTaq Universal SYBR
Green Supermix (Bio-Rad, Hercules, CA) in triplicate for the
CYP26A1 primers (forward: GGC CTT AGG AGC TGT GTA GG;
reverse: TTG TCC ACA GGA TAC ACG GT) and a GAPDH control
was used for normalisation (forward: ATGACATCAAGAAGGTGGC;
reverse: CATACCAGGAAATGAGCTTG). The thermocycling pro-
gramme was one cycle at 95 C for 5min, 95 C for 15 s, 60 C for
1min, followed by 40 cycles of 95 C for 15 s and 60 C for 1min
(CFX96 Real-Time System, C1000 Touch Thermal Cycler, Bio-Rad,
Hercules, CA). Melt curve analyses were performed from 65 C to
95 C, over 5min. Fold changes in CYP26A1 mRNA were calculated
according to the equation: 2(–Ct).
RNAseq analysis
RNA was extracted and 250 ng was processed using Illumina’s
TruSeq RNA sample prep kit version 2 (p/n RS-122-2001) according
to the manufacturer’s instructions. mRNA was isolated using Oligo
dT beads and the purified mRNA was chemically fragmented.
cDNA was generated using reverse transcriptase and random pri-
mers. Indexing adaptors were ligated and the cDNA libraries were
amplified by PCR. Samples were sequenced on a NextSeq 500
(Illumina, San Diego, CA) using a 43 bp paired end run. Data were
converted to fastq using Illumina bcl2fastq v2 and aligned to ref-
erence using TopHat2 (http://www.genomebiology.com/2013/14/
4/R36/abstract). Duplicate reads were removed (Picard v1.100) and
transcript abundance estimated with Python package HTSeq
(http://dx.doi.org/10.1093/bioinformatics/btu638). Differential
expression was determined using DESeq2 (http://doi.org/10.1186/
s13059-014-0550-8).
UV detection of RAMBAs
For standard curve measurement, RAMBAs were dissolved in etha-
nol and scanned for absorbance from 200 to 450 nm in a UVIKON
UV spectrophotometer with Lab Power Junior software. To quan-
tify C2 RAMBA in liposomes, the pre- and post-dialysis mixtures
were diluted 1:9 with ethanol and scanned at OD315. Background
absorbance of the lipids was measured at OD315, using empty lip-
osomes similarly dissolved in ethanol.
Results
RAMBA induction of CPY26A1 transcription
It is unclear what pattern of expression there is of CYP26
paralogues in neuroblastoma tumour cells. We thus analysed
expression of CYP26A-C using RNAseq datasets from tumour cell
lines LAN5, SK-N-SH, KELLY and IMR32 (Figure 1(A)). LAN5 and SK-
N-SH cell samples were either untreated or treated with ATRA
(5 mM) for 24 h. KELLY and IMR32 samples were from untreated
cells only. CYP26C mRNA is not detected except for very low levels
in IMR32. CYP26B1 is expressed in all lines in basal conditions and
is the most abundant paralogue in KELLY and IMR32. CYP26A1 is
expressed basally in each cell type except KELLY. CYP26B1 and
CYP26A1 are strongly induced up to 10,000-fold by ATRA in LAN5
and SK-N-SH. CYP26C1 is induced by ATRA, but only up to 10-fold,
in LAN5 and SK-N-SH cells. In this study, therefore, the RAMBA
effects are likely to be predominantly acting through CYP26A1
and CYP26B1.
In our experiments, we used two RAMBA compounds, one
based on an imidazole structure (C2) and one on triazole (C17)
[19] (Figure 1(B)). C2 and C17 have IC50 values of 3 nM and
0.35 nM, respectively, against CYP26 enzymes in vitro and can
enhance CYP26A1 mRNA induction by ATRA in SH-SY5Y [19]. To
assess RAMBA activity SK-N-SH cells (Figure 1(C)), cells were
treated with ATRA at either 0.5 mm or 0.1 mM, with or without the
addition of C2 at 2 mM or C17 at 1 mM. When using ethanol-solu-
bilised RAMBAs in SKNSH cells, the control cells contained the
equivalent amount of ethanol solvent (less than 0.2% v/v). ATRA
stimulated CYP26A1 transcription up to 1000-fold, whereas the
addition of either C2 or C17 induced a 20–30-fold further stimula-
tion of transcription. These data are therefore consistent with pre-
vious findings in SH-SY5Y [19], with the RAMBAs strongly
enhancing RA’s ability to stimulate CYP26A1 transcription.
Stimulation of morphological differentiation by RAMBAs
RAMBAs can enhance retinoid-induced differentiation in breast
cancer cells [24,33], but the equivalent biological or biochemical
responses downstream of RA in neuroblastoma cells have yet to
be demonstrated. A key characteristic of retinoid action in neuro-
blastoma cells is the induction of neuronal differentiation, charac-
terised by highly elongated neurites with growth cones and
neuron-like cell bodies [3]. To assess differentiation, C2 and C17
were used alone or in combination with ATRA to treat SK-N-SH
cells. Morphological differentiation was gauged by neurite out-
growth and the neuronal cell morphology. In contrast to RAMBAs
on breast cancer cells [24,33], RAMBAs C2 and C17 alone had no
obvious morphological effect in SK-N-SH (Figure 2(A)). The com-
bination treatments of RAMBAs plus ATRA, however, consistently
led to a more extreme morphological differentiation compared
with ATRA alone, generating more rounded and phase-bright neu-
rons with extensive processes compared with the more phase
dark, polygonal phenotype of ATRA-treated cells (Figure 2(A)).
These observations indicate that C2 and C17 can enhance retin-
oid-stimulation of morphological differentiation. Neurite length
quantitation showed that RAMBAs themselves did not affect neu-
rite outgrowth, whereas ATRA treatment did enhance outgrowth
(Figure 2(B)). Combination treatments showed that RAMBAs
enhanced this ATRA-induced neurite elongation. Increasing the
concentration of C17 from 1 mM to 10 mM did not further increase
the neurite effect. C2 and C17 RAMBAs can thus enhance the cel-
lular differentiation driven by ATRA in SK-N-SH cells.
Biochemical enhancement of retinoid action by RAMBAs
Retinoid stimulation of neuroblastoma cells induces a wide range
of biochemical changes, including enhancement of AKT phosphor-
ylation, which is required for neurite elongation in ATRA-treated
SK-N-SH cells [34,35]. If RAMBAs can enhance the biochemical
actions of ATRA, then we should observe a combination effect on
AKT phosphorylation. SK-N-SH cells were treated with 0.1 mM
ATRA for 72 h in the absence or presence of either 0.5 mM or
2 mM C2. Figure 2(C,D) shows that C2 can indeed enhance the
level of pAKT generated by ATRA. This effect was more pro-
nounced with the lower C2 concentration.
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Delivery of RAMBAs using liposomes
So far, we have provided the first demonstration that RAMBAs C2
and C17 can enhance both the biochemical and morphological
measures of ATRA signalling in SK-N-SH neuroblastoma cells. C2
and C17 can be delivered to cells after ethanol solubilisation, but
their high hydrophobicity would significantly limit their use in
Figure 1. (A) RNAseq analysis of LAN5, SK-N-SH (SH), KELLY and IMR32 cells shows the relative amounts of mRNA present for genes CYP26A1, CYP26B1 and CYP26C1.
mRNA levels after ATRA treatment for 24 h are also shown for LAN5 and SH cells. (B) Chemical structures of compounds C2 and C17, with their respective IC50 values
against CYP26A1 [19]. (C) Quantitative PCR was carried out on SK-N-SH cells after treatments with ATRA, RAMBA C2 and C17 and in combinations. Treatments were
for 72 h. The relative abundance of CYP26A1 mRNA is shown, normalised to untreated cells at 1.0. Error bars are standard deviations of triplicate, technical repli-
cates (n¼ 1).
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humans. A key objective of this work was therefore to assess
whether similar RAMBA bioavailability can be facilitated by incor-
porating these molecules into liposomal nanocomplexes. This
would be a proof of principle that nanotechnology could facilitate
cellular delivery of such RAMBAs, potentially increasing their thera-
peutic applicability.
To test liposomal delivery, the C2 and C17 RAMBAs were incor-
porated into liposomes composed of DOTMA, DOPC and choles-
terol (molar ratios 37.5%:37.5%:25%) suspended in water (see
Materials and Methods). These kinds of liposome formulations are
very effective for cellular delivery [36,37]. After sonication, posi-
tively charged liposomes with an average size of 91 nm (C17),
123 nm (C2) and 133 nm (empty) were obtained, with average PDI
values from 0.42 to 0.47 (Table 1). We tested only cationic liposo-
mal formulations in order to minimise charge-dependent, non-
specific uptake into cultured cells [38]. These liposome solutions
would contain, maximally, 240 mM of the RAMBAs and the data
below are presented on the basis of this maximal, theoretical
incorporation of RAMBAs into the liposomes. The tolerance of
neuroblastoma cells for our liposomes allowed us to deliver up to
2 mM of RAMBA without excessive liposomal cytotoxicity. At this
dose of RAMBA, a final concentration of 8.3 mg/ml of total lipid
would be added to the media. Liposomes were left on cells for
the whole treatment period, unless otherwise stated.
The C17 RAMBA liposomes were initially used to treat SK-N-
SH cells, to determine cellular tolerance and enhancement of
ATRA-induced differentiation. The data show that liposomal C17
enhances ATRA-induced neurite elongation as effectively as etha-
nol-dissolved C17 (Figure 3(A); compare to Figure 2). SK-N-SH
cells were also tested with RAMBA C2 packaged in liposomes
(Figure 3(B)). As additional controls, empty liposomes were used,
in media with or without added ATRA. Once again, liposome
packaging of C2 permits the RAMBA to enhance the ATRA-
induced neurite elongation by approximately 60% (p value .06).
Preliminary data from LAN5 cells, another line that differentiates
in response to ATRA, show a similar trend (not shown).
Liposome-treated cells again showed that RAMBA co-treatment
with ATRA enhanced the morphological shift towards highly
rounded cell bodies (Figure 4; compare to Figure 2). These data
collectively indicate that RAMBAs C2 and C17 can be successfully
delivered to neuroblastoma cells in liposomes, where they
enhance ATRA-dependent differentiation to a similar level as
seen with ethanol-delivered RAMBAs (compare Figure 2 with
Figure 4).
Figure 2. (A) SK-N-SH cells were treated with ATRA alone, or in combination with RAMBA C2 or C17, for 72 h. RAMBAs by themselves had no effect on cell morph-
ology. In combination with ATRA, RAMBAs induce a highly rounded, refractile morphology (insets). Scale bar ¼ 50 mm (25 mm for insets). (B) SK-N-SH cells were
treated with 0.1 mM ATRA and RAMBAs C2 and C17 for 72 h and neurite lengths were measured (n¼ 3). Standard deviations are shown. ANOVA comparisons show
where mean neurite lengths are significantly longer compared with ATRA alone (Bonferroni’s and Dunnett’s post hoc corrections p<.05; p<.01). (C) SK-N-SH cells
were treated for 72 h with ATRA, RAMBA C2 and combinations. Immunoblotting shows relative levels of pAKT and AKT present in cell lysates. (D) Protein bands were
quantified and mean pAKT intensities were normalised against AKT and compared using ANOVA (n¼ 3). Controls are untreated cells. SD are shown, p<.01 com-
pared to ATRA alone.
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Empty liposome treatment generated no morphological effects
(Figure 4). However, when combined with ATRA, we did some-
times observe an increased refractility of cells, but not as extreme
as with the RAMBA liposome (Figure 4). Although not currently
understood, empty liposomes may have some limited propensity
to enhance ATRA, possibly by binding to RA through their positive
charge or by attracting RA through its hydrophobic quality.
Liposomal RAMBAs enhance ATRA-induced AKT signalling
As shown in Figure 2, RAMBAs can enhance pAKT levels in the
presence of ATRA. To assess whether liposomal RAMBAs retain
this activity, SK-N-SH cells were treated with C17 liposomes and
ATRA (Figure 5(A)). The combination treatments again enhance
pAKT levels above those seen with single treatments. Further
experiments were carried out with C2 liposomes, empty liposomes
and lower levels of ATRA (0.05 mM) (Figure 5(B)). Again, the C2 lip-
osomes specifically increased pAKT stimulation in combination
with ATRA. This effect may be close to maximal with 0.5 mM C2,
since 2 mM C2 showed a lesser stimulation of pAKT (although not
statistically different from the 0.5 mM mean), possibly due to mild
detrimental effects of the higher lipid treatment. pAKT activation
was comparable between ethanol-delivered C2 and liposomal C2
(compare Figure 5 and Figure 2(C)). Preliminary data using C17
also show pAKT stimulation (Supplementary Figure 2).
N-myc suppression by RAMBAs and retinoids
C2 and C17 are capable of enhancing ATRA actions as judged by
pAKT and differentiation. A further outcome of retinoid treatment
in neuroblastoma cells is the suppression of N-myc protein levels
[39,40]. We therefore tested whether liposomal RAMBAs were cap-
able of enhancing N-myc suppression by ATRA. The MYCN-ampli-
fied cell line LAN5 was treated with liposomes and low levels of
ATRA for 24 h. Figure 5(C) shows the modest N-Myc response with
ATRA at this 0.05 mM dose, but an enhanced suppression of N-
Myc in cells treated with the ATRA and C2 liposome combination.
The collective data therefore indicate that RAMBAs encapsu-
lated in liposomes have good bioavailability in neuroblastoma
cells and are effective at augmenting ATRA signalling as evi-
denced by enhanced neurite elongation, AKT phosphorylation and
N-myc suppression.
Sustained morphological differentiation after RAMBA
liposome delivery
Previous data in the field indicate that liposomes bind to cells
maximally within 4–6 h [41,42]. We wished to test if liposomal
RAMBAs retained extended activity after a short cellular treatment.
We treated LAN5 cells with liposomes for 24 h and this cell media
was then removed and replaced with fresh media containing only
ATRA. Figure 6 shows that C2 liposome pre-treatment still led to
enhanced ATRA-dependent neurite elongation, six days after lipo-
some removal. Thus, RAMBAs in liposomes can be delivered to
these tumour cells and will trigger a sustained, combination
response with ATRA for several days.
ATRA suppression of cell growth is enhanced by
liposomal RAMBAs
RAMBAs enhance retinoid-induced growth suppression in breast
cancer cells [24,33], but the equivalent has yet to be
Table 1. Liposome parameters.
Liposome content Average size in nm (range) SD Average PDI SD Average charge (mV) SD
RAMBA C17 (n¼ 3) 90.9 (82–107) 12.3 0.42 0.02 64.0 7.9
RAMBA C2 (n¼ 6) 123.0 (80–164) 30.4 0.42 0.09 62.5 4.6
Empty (n¼ 6) 133 (100–154) 20.5 0.47 0.14 63.0 5.1
Independent batches of liposomes were made (n, number of batches) and analysed in a Zetasizer Nano ZS for size (diameter in nm), polydis-
persity index (PDI) and average charge (mV). The standard deviation of each set of batches is given.
Figure 3. (A) SK-N-SH cells were treated for 72 h with 0.1 mM ATRA, C17-containing liposomes, or combinations of the two. Controls (con) are untreated and maximal
concentrations of RAMBAs are indicated. Neurites were measured and statistical comparison made against the mean of ATRA single treatment. SD are shown, p<.05,p<.01; n¼ 3. (B) SK-N-SH cells were treated for 72 h with 0.1 mM ATRA, C2-containing liposomes, empty liposomes and combinations (n¼ 3). SD are shown,p<.05, p<.01 using ANOVA.
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demonstrated in neuroblastoma cells. RA increases differentiation
in some neuroblastoma cell lines and in others it can reduce pro-
liferation as well as, or instead of differentiation. We therefore
tested the ability of liposomal RAMBAs to enhance the ability of
ATRA to suppression cell proliferation.
When used alone, ATRA suppressed LAN5 and KELLY cell prolif-
eration. We also compare 13-cis-RA to ATRA, since 13-cis-RA is
used clinically in neuroblastoma treatment. A broadly comparable
pattern of growth suppression was observed (Figure 7(A,B)). In
KELLY, the EC50 value for ATRA was approximately 0.6 mM, and
0.3 mM for 13-cis-RA. In LAN5, both EC50 values were approxi-
mately 0.3 mM. This indicates that under these conditions the two
retinoids act similarly in LAN5, and in KELLY the 13-cis-RA is
slightly more effective. The 13-cis-RA is thus likely isomerised effi-
ciently into intracellular ATRA in these cells.
The cells’ responses to treatment with either empty lipo-
somes or C2-containing liposomes were assessed. Cells were
treated with 80 nM or 160 nM ATRA, well below its EC50, for
six days, alongside either 0.5 mM C2 liposomes or the equivalent
amount of empty liposomes to match the lipid dose. C2 lipo-
somes were able to significantly suppress growth in ATRA-
treated KELLY and LAN5 cells compared with minimal growth
suppression by ATRA alone (Figure 7(C,D)). In ATRA-treated
KELLY cells, C2 liposomal treatment suppressed growth more
than the empty liposomes. In LAN5 cells, both liposome formu-
lations somewhat suppressed cell proliferation at 0 mM ATRA,
although this did not reach significance. C2 liposomes plus
ATRA showed a suppression of LAN5 growth compared with
ATRA alone, whereas the empty liposomes did not. At higher
levels of ATRA up to 1 mM, the C2 liposomes could still suppress
cell growth (Supplementary Figure 3). These data demonstrate
that C2 liposomes can enhance the growth suppression driven
by ATRA, corroborating what was found with neurite elongation,
N-myc suppression and AKT activation.
Figure 4. (A) SK-N-SH cells were treated for 72 h with 0.1 mM ATRA, 2 mM C2 liposomes (C2), 0.5 mM C17 liposomes (C17) and combinations thereof. Phase contrast
images show that liposomal RAMBAs in combination with ATRA generated highly rounded, neuron-like cells (arrows); 2 enlargements are shown below the main
panels. (B) SK-N-SH cells treated for 72 h with empty liposomes (EL) with or without 0.05 mM ATRA, and 0.5 mM C17 liposomes plus 0.05 mM ATRA. Scale bar ¼
50 mm for rows 2, 4 and 5; 100 mM for rows 1 and 3. Maximal, hypothetical concentrations of the RAMBAs are indicated.
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C2 packaging efficiency in liposomes
The experiments described so far assumed the maximal dose esti-
mates of C2 and C17 when encapsulated in liposomes. Maximal
encapsulation, however, is not routinely achieved with liposomal
formulations. During the completion of our biochemical and cellu-
lar analyses, we were able to successfully develop a UV assay and
this was used to assess the actual RAMBA concentrations in lipo-
somal formulations.
RAMBAs were first solubilised in ethanol and UV absorbance
scans were performed from 200 to 450 nm (Figure 8(A)). A peak at
315 nm was chosen for generating a standard curve since this
wavelength showed low background absorbance by empty lipo-
somes (see below). To calculate the amount of C2 and C17 pre-
sent in liposomes, each batch of RAMBA liposomes was dissolved
in ethanol at 10% v/v, and UV scans performed (Figure 8(B)).
Empty liposomes were similarly scanned for background subtrac-
tion. The physical parameters of these particular liposomes are
given in Supplementary Table 1. Compared to the maximal theor-
etical packaging value of 240 mM, the actual encapsulation effi-
ciency of the RAMBAs was 64–79% for C2 and 71–91% for C17
(Figure 8(B)). Based on this, the doses used in our cellular experi-
ments with liposomal RAMBAs could be overestimated from
between 10% and 30%.
We also assessed RAMBA retention in the liposomes, by dialys-
ing the liposomes over 24 h and quantifying the remaining
RAMBA (Figure 8(B)). This showed that 72–84% of C2 remained
encapsulated after dialysis, and 81–95% of C17 was retained. The
C17 sample 3 was left for four days before dialysis and these still
retained 95% of the original RAMBA, indicating that nearly all of
the RAMBA is retained over this extended time period.
To test if the RAMBA liposomes retained activity after dialysis,
we tested the ability of dialysed C2 liposomes to induce morpho-
logical differentiation and AKT activation. The dialysed liposomes
retained their qualitative effects on ATRA-induced differentiation,
generating highly rounded, phase bright neurons (Supplementary
Figure 1). Biochemically, the dialysed liposomes also enhanced
ATRA stimulation of pAKT levels similarly to their non-dialysed
liposome counterparts over this shorter 24 h assay (Figure 8(C)).
Figure 5. (A) SK-N-SH cells were treated for 72 h with ATRA, C17 liposomes (C17 lipo), or combinations. Immunoblotting shows levels of pAKT and AKT; the untreated
lane is from the same blot. (B) A second experiment is shown in which SK-N-SH was treated with ATRA alone, or in combinations with empty liposomes or C2 lipo-
somes (C2 lipo). Immunoblotting of pAKT and AKT is shown. (C) LAN5 cells were treated for 24 h with 0.1 mM ATRA alone and in combinations with empty liposomes
and C2-containing liposomes. Immunoblotting shows levels of N-myc and actin. Two independent experiments are shown and maximal, hypothetical concentrations of
the RAMBAs are indicated.
Figure 6. SK-N-SH cells were treated with empty liposomes or C2 liposomes for
24 h. The media was then replaced, with and without 0.05 mM ATRA, and the
cells were cultured for six more days. Neurite lengths were measured and
means± SD are shown (n¼ 3). ANOVA shows significant difference p<.05.
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Figure 7. (A, B) KELLY and LAN5 cells were plated in 96-well plates and grown in the presence of a range of concentrations of ATRA or 13-cis-RA. The relative cell sur-
vival was measured after six days and plotted with means and SD (n¼ 3); zero ATRA is treated as 100% survival. (C, D) Cell proliferation rates were assessed in KELLY
and LAN5 cells after treatment for six days with zero, 80 nM or 160 nM ATRA, plus either empty liposomes or C2-containing liposomes at 0.5 mM C2 (maximal concen-
tration) (n¼ 3). ANOVA analysis was performed, and SDs are shown. p<.05; ns: not significant (p>.05).
Figure 8. Assessment of the loading and retention of RAMBAs in liposomes. (A) A UV spectrophotometric scan of 100 mM C17 dissolved in ethanol. (B) Table showing
independent preparations of liposomes tested for the amount of RAMBA present, expressed as a percentage of the theoretical maximum of 240 mM. The percentage
of this RAMBA that remained after a 24 h dialysis against distilled water is given, as well as the time delay between liposome synthesis and the dialysis.
(C) Immunoblot of pAKT, AKT and actin from KELLY cells that were treated for 24 h with C2-containing liposomes before (C2) or after (C2-D) dialysis, empty liposomes
before (EL) or after (EL-D) dialysis, with or without co-treatment with 0.1 mM ATRA (RA).
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Discussion
RA has proven to be a beneficial biological therapeutic in leukae-
mia and neuroblastoma and in several keratinisation disorders
[11,43]. Although the potential clinical benefits of retinoids are
broad, there are significant, practical challenges with their sys-
temic delivery. For paediatric diseases such as neuroblastoma in
particular, dosing is physically difficult and off-target toxicity is
well documented [44,45]. ATRA and 13-cis-RA also have poor
pharmacokinetics and are metabolised in vivo by induced CYP26
enzymes [2,6]. Lastly, retinoid resistance often develops in cancer
patients, being caused in part by sustained upregulation of the
same CYP26 enzymes [7–9,46]. Given the relatively modest clinical
benefit of current RA treatment in neuroblastoma [2], there is a
continued need to understand whether there is greater efficacy
still to be gained and where the long-term potential lies.
Interest in RAMBAs in recent years has focussed on whether
these RA metabolism blockers could be practicable tools for
enhancing RA efficacy and reducing resistance. RAMBAs may also
increase the intracellular activity of RA without significantly
increasing its systemic toxicity. Previous work by Armstrong et al.
had shown that the CYP26 inhibitor R116010, co-applied with 13-
cis-RA in animals, reduces 13-cis-RA metabolism in the liver, lead-
ing to higher levels of serum 13-cis-RA and ATRA, plus greater
CYP26A1 transcription in xenografted SH-SY5Y tumours [18]. That
study demonstrated that CYP26-specific RAMBAs sustained
increased 13-cis-RA levels in the blood, showing a systemic bene-
fit. Extrapolation to humans is uncertain, however, since the speci-
ficity of R116010 towards murine CYP enzymes was questioned.
Although R116010 has also been shown to suppress breast cancer
cell growth [47], this drug was not developed further and clinical
trials did not progress. Instead of R116010, we used RAMABA C2
and C17 here to assess RAMBA potential in cultured neuroblast-
oma cells. C2 has a similar IC50 to R116010 (3 nM), whereas the
IC50 of C17 is 10-fold lower (0.35 nM) [19]. These RAMBAs could
therefore be very effective CYP26 inhibitors for use in vivo, but
only if they can be delivered at effective doses. However, their
high hydrophobicity presents a barrier to this, and we have
addressed this in this study by testing their delivery to cells using
liposome nanotechnology.
RAMBAs C2 and C17 delivered after ethanol solubilisation
alongside ATRA, induced high levels of CYP26A1 mRNA transcrip-
tion in SK-N-SH cells, agreeing with previous studies [19]. We then
demonstrated for the first time that C2 and C17, when dissolved
in ethanol and combined with ATRA, could stimulate ATRA-
dependent neuronal differentiation as judged by increased neurite
elongation, and increased pAKT activation. These RAMBAs can
therefore enhance ATRA action at a morphological and biochem-
ical level in these tumour cells. To our knowledge, RAMBAs have
not be delivered using nanotechnology before and we have there-
fore provided the first demonstration that these hydrophobic mol-
ecules can be incorporated effectively into liposomes. In such a
context, they retain bioavailability and an activity that is at least
comparable to that seen with their ethanol-dissolved counterparts.
These liposomal RAMBAs enhanced ATRA-driven neurite extension
and AKT activation in SK-N-SH cells, led to greater suppression of
N-myc protein and enhanced the growth-suppressive properties
of ATRA. Collectively, these data demonstrate that CYP26-specific,
hydrophobic RAMBAs can be effectively incorporated into lipo-
somes where their bioavailability remains effective at enhancing
ATRA actions in neuroblastoma-derived cell lines.
These effects of liposomal RAMBAs were achieved using com-
bined retinoid concentrations as low as 50–80 nM in KELLY and
IMR32 cells, a level that is readily achievable clinically [48,49]. The
serum levels of 13-cis-RA given to children in current dosing regi-
mens peaks at a mean of 2.8 mM [48] or 6.9 mM [49], depending
on the study, but then drops rapidly to sub-micromolar levels
within 6 h. This raises the possibility that co-treatment with liposo-
mal RAMBAs such as C2 or C17 may be able to prolong the effect-
ive, active dose of retinoids in cells, or may even allow lower, less
toxic retinoid doses to be used in vivo. Of perhaps more rele-
vance, the liposomal approach, if targeted correctly, could
increase the local action of retinoids while minimising off-target
toxicities in normal tissues. Furthermore, our sequential treatment
of cells with liposomes then with ATRA, indicated that a single lip-
osomal delivery can generate a sustained enhancement of ATRA-
induced differentiation over several days. This could be of clinical
relevance if translated to a similar effect in vivo, as an infrequent
dose of RAMBA nanocomplexes may enhance and prolong the
action of the currently used, daily retinoid treatment. This war-
rants pre-clinical studies in vivo in order to test this hypothesis.
One question with RAMBAs is what their best target in vivo
would be. For example, should they be targeted to the liver,
where there is significant CYP26 induction, or to the tumours tis-
sues? Our study was done in tissue culture, focussing on the
tumour-derived cells themselves, where the RAMBAs are certainly
effective. Their effectiveness systemically in vivo is more difficult
to predict at this stage. Retinoids are efficiently destroyed in the
liver and so it could be argued that RAMBAs should be targeted
there in order to maintain systemic retinoid levels. Nevertheless, it
may be equally effective to target the solid tumours themselves
directly. The possibility of delivering RAMBAs alongside RA in
combined liposome formulations should also be considered.
Although the liposomes employed in our study are conven-
tional in design and suitable for in vitro experiments, further mod-
ifications will be required for optimal targeting in vivo [27,50].
These modifications could include alterations in concentration of
the neutral lipid cholesterol to reduce toxicity, or incorporation of
polyethylene glycol (PEG), which reduces aggregations and bind-
ing of serum proteins. Targeting peptides should also be consid-
ered, for directed uptake into neuroblastoma tumours, as
demonstrated in xenografts [51,52], where they can extravasate
and concentrate in the tumour, potentially using the enhanced
permeation and retention effect [53]. There are numerous further
liposome formulations in the clinic or in trials, with a range of bio-
physical and biochemical properties [25,27,28], so optimised
tumour cell targeting should be achievable. Improved targeting
may again facilitate the use of lower systemic doses of RA
in children.
We noted that our empty liposomes appeared to sometimes
weakly enhance the effects of ATRA. The liposomes’ positive
charge could possibly play a role in adsorbing ATRA under some
circumstances and future studies could evaluate if neutral or
anionic liposomes have similar effects. As an alternative approach,
we would also consider co-incorporation of RAMBAs and RAs into
cationic liposomes for co-delivery in vivo. This may further reduce
off-target toxicities of the retinoids.
In conclusion, hydrophobic RAMBAs derived from imidazole
and triazole scaffolds with high specificity for CYP26 enzymes, can
be delivered successfully to neuroblastoma cells in liposomes.
They enhance the cellular and biochemical actions of RA in SK-N-
SH, LAN5, IMR32 and KELLY cells. Not all neuroblastoma tumour
cells however will induce CYP26 in response to RA [18] and so, as
with most drugs approaches, the benefits of RAMBAs may be
restricted to RA-responsive neuroblastoma tumours and resistant
tumours where resistance is CYP26 enzyme-based. Use of nano-
technology to deliver RAMBAs could also be considered for
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applications in other cancers such as basal cell carcinoma [54],
lymphoid malignancies [55] and others, where retinoids are either
used clinically or show promise from pre-clinical models [10]. This
study has provided a proof of principle and the basis for further
investigation of nanotechnology as a delivery pathway for hydro-
phobic RAMBAs in combination with retinoids, with the goal of
increasing the efficacy of retinoid actions in target tissues and
improving clinical outcomes.
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